### 2.2.1 In vitro / physico-chemical Data

A literature search was performed to collect available information on physiochemical properties of verapamil. The obtained information from literature is summarized in the table below. 

| **Parameter**   | **Unit** | **Value**       | Source                                                       | **Description**                                 |
| :-------------- | -------- | --------------- | ------------------------------------------------------------ | ----------------------------------------------- |
| MW              | g/mol    | 454.6     | https://www.drugbank.ca/                                     | Molecular weight                                |
| pK<sub>a</sub>  | 8.92  | (base)          | [Perdaems 2010](#5-References)               | Acid dissociation constant                      |
| Solubility (pH) | mg/L     | 46.0 | [Heikkinen 2012](#5-References) | Water solubility                               |
| logP            |  | 2.7                       | [Sandström 1999](#5-References) | Partition coefficient between octanol and water |
| fu              |         | 0.1 | [Vogelpoel 2004](#5-References) | Fraction unbound in plasma                      |
| KI             | µmol/L | 1.2 | [Rowland-Yeo 2011](#5-References) | Inhibition constant    |
| kinact   		| 1/h | 2.8 | [Rowland-Yeo 2011](#5-References) | Rate of enzyme inactivation   |


### 2.2.2 Clinical Data

A literature search was performed to collect available clinical data on verapamil in healthy adults.

#### 2.2.2.1 Model Building and parameterizing of CYP3A4 interaction

The following studies were used for model building and parameterization of CYP3A4 interaction:

| Publication                      | Arm / Treatment / Information used for model building        |
| :------------------------------- | :----------------------------------------------------------- |
| [Barbarash 1988](#5-References)  | Healthy subjects receiving single intravenous doses of 10 mg and single oral doses of 120 mg |
| [Johnston 1981](#5-References)   | Healthy subjects receiving single intravenous doses of 0.1 mg/kg and single oral doses of 120 mg |
| [McAllister 1982](#5-References) | Healthy subjects receiving single intravenous doses of 10 mg and single oral doses of 120 mg |




#### 2.2.2.2 Model verification 

The following studies were used for model verification:

| Publication                      | Arm / Treatment / Information used for model building        |
| :------------------------------- | :----------------------------------------------------------- |
| [Maeda 2011](#5-References)      | Healthy subjects receiving single oral doses of 80 mg |
| [Streit 2005](#5-References)    | Healthy subjects receiving single intravenous doses of 5 mg |
| [Hla 1987](#5-References)       | Healthy subjects receiving multiple oral doses of 120 mg BID |
| [Joergenson 1988](#5-References) | Healthy subjects receiving multiple oral doses of 120 mg BID |
| [Shand 1981](#5-References)     | Healthy subjects receiving multiple oral doses of 120 mg TID |
| [Johnson 2001](#5-References)   | Healthy subjects receiving multiple oral doses of 400 mg verapamil  QD. On day 14, subjects receive a single oral verapamil dose of 3 mg. |
| [Karim 1995](#5-References)     | Healthy subjects receiving single oral doses of 240 mg |


